Abstract

目的比较亲属单倍型供者(HID)和同胞全合供者(MSD)异基因造血干细胞移植(allo-HSCT)后患者出血性膀胱炎(HC)的发生率及临床特征。方法对2011年1月至2012年12月接受清髓性预处理行allo-HSCT的609例恶性血液病患者(HID组406例、MSD组203例)中发生HC的病例进行回顾性分析,对两组患者HC的发生率及临床特征进行比较。结果HID组和MSD组发生HC者分别为183例和17例,累积发生率分别为(45.6±2.5)%和(8.5±2.0)%(χ2=77.331,P<0.001),重度HC(Ⅲ~Ⅳ度)累积发生率分别为(11.2±1.9)%和(2.1±1.1)%(χ2=12.883,P<0.001),前者均显著高于后者,差异有统计学意义。两组患者HC发生的中位时间分别为移植后27(0~177)d和29(6~72)d(P=0.766),HC持续中位时间分别为21(3~157)d和13(5~67)d(P=0.182),治疗总有效率分别为69.9%和70.6%(χ2=0.003,P=1.000),差异均无统计学意义。结论HID组移植后HC发生率和重度HC发生率均较MSD组增高,两组患者HC发生和持续的中位时间及临床疗效差异均无统计学意义。

Full Text
Paper version not known

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.